Figure 2.
CHIP is associated with impaired recovery from AKI in the ASSESS-AKI study.
A) Prevalence of CHIP among individuals with a resolving AKI pattern (n = 191) compared to a non-resolving AKI pattern (n = 130), as defined by Bhatraju et al.5 B) Odds of non-resolving AKI pattern by CHIP status, adjusted for age, sex, baseline creatinine, AKI stage, smoking status, race, and history of diabetes, hypertension, and cardiovascular disease. C) Risk of significant kidney function impairment (primary study composite outcome of ESKD or eGFR decline by ≥50%) over 5 years of follow-up among ASSESS-AKI participants with baseline AKI by CHIP status, adjusted for age, sex, baseline creatinine, AKI stage, smoking status, race, and history of diabetes, hypertension, and cardiovascular disease.